Biomedical Science Letters

eISSN 2288-7415

Table. 1.

US FDA-approved ADCs

Drug Maker Condition Trade name Target Approval year
Gemtuzumab ozogamicin Pfizer/Wyeth Relapsed acute myelogenous leukemia (AML) Mylotarg CD33 2017; 2000
Brentuximab vedotin Seattle Genetics, Millennium/Takeda Relapsed HL and relapsed sALCL Adcetris CD30 2011
Trastuzumab emtansine Genentech, Roche HER2-positive metastatic breast cancer (mBC) following treatment with trastuzumab and a maytansinoid Kadcyla HER2 2013
Inotuzumab ozogamicin Pfizer/Wyeth Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia Besponsa CD22 2017
Moxetumomab pasudotox Astrazeneca Adults with relapsed or refractory hairy cell leukemia (HCL) Lumoxiti CD22 2018
Polatuzumab vedotin-piiq Genentech, Roche Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Polivy CD79 2019
Enfortumab vedotin Astellas/Seattle Genetics Adult patients with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy Padcev Nectin-4 2019
Trastuzumab deruxtecan AstraZeneca/Daiichi Sankyo Adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens Enhertu HER2 2019
Sacituzumab govitecan Immunomedics Adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease Trodelvy Trop-2 2020
Belantamab mafodotin-blmf GlaxoSmithKline (GSK) Adult patients with relapsed or refractory multiple myeloma Blenrep BCMA 2020
Loncastuximab tesirine-lpyl ADC Therapeutics Large B-cell lymphoma Zynlonta CD19 2021

Source: Biochempeg Worldwide PEG Supplier home page ( (Biochempeg, 2021)

Biomed Sci Letters 2021;27:121-33
© 2021 Biomed Sci Letters